The NSABP has randomized more than 100,000 patients with diagnoses of breast or colorectal cancers into clinical trials during the past 50 years. Based on incremental benefit achieved through multiple evolutionary steps of treatment modalities tested in those trials, significant improvement in patient outcomes has been achieved overall. However, this approach also means that there has been significant over-treatment of some patients who did not benefit from the various interventions, which now have become part of legacy treatments to which newer agents are added. Development of reliable prognostic and predictive tests is required to deliver the goal of more personalized treatment. Since, for ethical reasons, trials cannot be conducted again once the efficacy of newer regimens is demonstrated, archived tumor tissue blocks from historical trials conducted by the NSABP provide an essential resource to investigators who are trying to develop such tests. The NSABP Biospecimen Bank at the NSABP Division of Pathology Tissue Bank houses tumor-tissue specimens from more than 87,000 patients and serves as an open resource to the scientific community to provide tissues for development and clinical validation of new prognostic or predictive tests. Tissue specimens are provided to investigators from both academia and the private sector on the basis of scientific merit. A multi-gene expression based prognostic test (OncotypeDx) developed in a collaboration between the private sector and the bank has become a standard in clinical management of hormone receptor positive node negative breast cancer in the United States. In-house development and/or optimization of methods for whole-genome gene-expression analyses and mutation profiling of formalin-fixed, paraffin-embedded blocks further enhances the value of the NSABP Biospecimen Bank.

Public Health Relevance

Since clinical trials cannot be conducted again purely for biomarker discovery or validation, archived tissue blocks from completed trials provide an essential resource for biomarker development. Using NSABP Biospecimen Bank resources, the OncotypeDx assay for prognostication of breast cancer was developed and provided a benchmark for clinical prognostic assay development and validation.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Resource-Related Research Projects--Cooperative Agreements (U24)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRLB-5 (M1))
Program Officer
Lubensky, Irina
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Nsabp Foundation, Inc.
United States
Zip Code
Margolese, Richard G; Cecchini, Reena S; Julian, Thomas B et al. (2016) Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet 387:849-56
Dalerba, Piero; Sahoo, Debashis; Paik, Soonmyung et al. (2016) CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. N Engl J Med 374:211-22
Wolmark, Norman; Mamounas, Eleftherios P; Baehner, Frederick L et al. (2016) Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/Nati J Clin Oncol 34:2350-8
Ganz, Patricia A; Cecchini, Reena S; Julian, Thomas B et al. (2016) Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet 387:857-65
Chapman, Judith-Anne W; Costantino, Joseph P; Dong, Bin et al. (2015) Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29. Breast Cancer Res Treat 153:353-60
Ingle, James N (2013) Pharmacogenomics of endocrine therapy in breast cancer. J Hum Genet 58:306-12
Pogue-Geile, Kay; Yothers, Greg; Taniyama, Yusuke et al. (2013) Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08. J Natl Cancer Inst 105:989-92
Ingle, James N; Liu, Mohan; Wickerham, D Lawrence et al. (2013) Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention. Cancer Discov 3:812-25
Gavin, Patrick G; Colangelo, Linda H; Fumagalli, Debora et al. (2012) Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res 18:6531-41
Schroen, Anneke T; Petroni, Gina R; Wang, Hongkun et al. (2012) Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from U.S. Cooperative Oncology Groups. Clin Cancer Res 18:256-62

Showing the most recent 10 out of 25 publications